# Practical Feasibility Assessment: Synaptic Pruning Therapeutics
## Hypothesis 1: Complement C1q Mimetic Decoy Therapy
**Revised Confidence: 0.45**
### Druggability Assessment
**Target Class:** Protein-protein interaction (PPI) - historically challenging but increasingly tractable
**Chemical Matter:**
- **Large molecule approach:** Engineered proteins/peptides mimicking C1q globular heads (22 kDa each)
- **Small molecule approach:** PPI inhibitors targeting C1q-CR3 interface (challenging given large interaction surface ~1,500 Ų)
- **Best bet:** Antibody-based decoys or engineered protein fragments
### Existing Tools/Clinical Candidates
- **C5 inhibitors:** Eculizumab (Soliris), Ravulizumab (Ultomiris) - approved but target downstream
- **C1 esterase inhibitors:** Berinert, Cinryze - approved for hereditary angioedema
- **Research tools:** Anti-C1q antibodies (ANX005 - ANI Pharmaceuticals, Phase 2 for ALS)
- **Closest analogue:** None directly targeting C1q-microglial interactions
### Competitive Landscape
- **Direct competitors:** None identified
- **Indirect competitors:**
- Neurimmune's aducanumab pathway (failed)
- Annexon Biosciences (ANX005) - targeting C1q in neurodegeneration
- Complement therapeutics focused on AMD/PNH markets
### Safety Concerns
- **Immunocompromise risk:** C1q essential for immune complex clearance
- **Autoimmune disease risk:** C1q deficiency → SLE-like syndrome
- **Infection susceptibility:** Complement system critical for bacterial defense
- **Immunogenicity:** Engineered proteins likely antigenic
### Cost & Timeline
- **Discovery-IND:** $15-25M, 4-5 years (protein engineering, PK/PD optimization)
- **Phase I/II:** $30-50M, 3-4 years
- **Major hurdle:** Demonstrating CNS penetration of large molecules
- **Total to proof-of-concept:** $45-75M, 7-9 years
**Verdict:** **Moderate feasibility** - technically challenging but validated biology
---
## Hypothesis 4: Purinergic P2Y12 Inverse Agonist Therapy
**Revised Confidence: 0.58**
### Druggability Assessment
**Target Class:** GPCR - highly druggable
**Chemical Matter:**
- **Existing scaffolds:** Thienopyridines, non-thienopyridine P2Y12 antagonists
- **Chemistry starting point:** Modify clopidogrel/ticagrelor analogs for inverse agonism
- **CNS penetration:** Major challenge - need to optimize beyond current P2Y12 inhibitors
### Existing Tools/Clinical Candidates
**Approved P2Y12 antagonists:**
- Clopidogrel (Plavix) - prodrug, limited CNS penetration
- Ticagrelor (Brilinta) - reversible, better CNS penetration
- Prasugrel (Effient) - irreversible, limited CNS penetration
**Research compounds:**
- **Cangrelor** (IV only) - reversible, research tool
- **PSB-0739** - potent antagonist, research grade
- **No known inverse agonists** in clinical development
### Competitive Landscape
- **Platelet market:** Saturated ($10B+ annually)
- **CNS P2Y12 space:** Completely open
- **Potential players:** AstraZeneca, Bristol Myers Squibb (existing P2Y12 expertise)
- **Academic centers:** Strong P2Y12 research at University of Missouri, King's College London
### Safety Concerns
- **Bleeding risk:** Major concern if systemic exposure occurs
- **CNS selectivity critical:** Need >100-fold selectivity vs peripheral P2Y12
- **Microglial dysfunction:** Risk of impairing beneficial surveillance functions
- **Drug-drug interactions:** P2Y12 inhibitors interact with anticoagulants
### Cost & Timeline
- **Discovery-IND:** $8-15M, 3-4 years (medicinal chemistry optimization for CNS penetration)
- **Phase I:** $10-20M, 18 months (extensive bleeding/platelet function monitoring)
- **Phase IIa:** $25-40M, 2-3 years
- **Total to proof-of-concept:** $43-75M, 6-8 years
**Verdict:** **High feasibility** - excellent target class, clear medicinal chemistry path
---
## Hypothesis 2: Fractalkine Axis Amplification via CX3CR1 PAMs
**Revised Confidence: 0.52**
### Druggability Assessment
**Target Class:** GPCR - highly druggable
**Chemical Matter:**
- **PAM chemistry:** Limited precedent for chemokine receptor PAMs
- **Starting scaffolds:** CX3CR1 antagonist chemotypes could be modified
- **Allosteric sites:** Poorly defined - would require extensive structure-based drug design
### Existing Tools/Clinical Candidates
**CX3CR1 antagonists (could inform PAM design):**
- **AZD8797** (AstraZeneca) - Phase II for COPD (discontinued)
- **GSK163090** (GSK) - preclinical
- **Research tools:** Various academic compounds with limited drug-likeness
**CX3CR1 PAMs:** None known in development or research
### Competitive Landscape
- **Chemokine receptor space:** Historically challenging (many failures)
- **CX3CR1 specifically:** No active clinical programs identified
- **Fractalkine therapeutics:** Recombinant CX3CL1 investigated briefly, abandoned
### Safety Concerns
- **Unknown PAM effects:** No precedent for CX3CR1 positive allosteric modulation
- **Immune system effects:** CX3CR1 expressed on NK cells, T cells, monocytes
- **Potential for receptor desensitization:** Risk with chronic GPCR activation
### Cost & Timeline
- **Discovery-IND:** $12-20M, 4-5 years (novel PAM discovery, extensive optimization)
- **High failure risk:** 70%+ given limited precedent
- **Phase I/IIa:** $30-45M, 3-4 years
- **Total to proof-of-concept:** $42-65M, 7-9 years
**Verdict:** **Moderate-low feasibility** - druggable target but high technical risk
---
## Hypothesis 6: Metabolic Reprogramming via Microglial Glycolysis Inhibition
**Revised Confidence: 0.48**
### Druggability Assessment
**Target Class:** Metabolic enzymes - well-established druggability
**Chemical Matter:**
- **HK2 inhibitors:** 2-Deoxy-D-glucose, 3-bromopyruvate, lonidamine analogs
- **PFKFB3 inhibitors:** 3PO, PFK15, AZ26 (research compounds)
- **Brain penetration:** 2-DG crosses BBB but lacks selectivity
### Existing Tools/Clinical Candidates
**Glycolysis inhibitors in oncology:**
- **2-Deoxy-D-glucose:** Phase I/II trials in cancer (limited efficacy)
- **Lonidamine:** Phase III trials (mixed results, discontinued)
- **3-Bromopyruvate:** Preclinical only (toxicity concerns)
**CNS-specific approaches:** None in clinical development
### Competitive Landscape
- **Cancer metabolism:** Crowded field with multiple failures
- **CNS metabolism:** Open field but high technical barriers
- **Platform technologies:** Companies like Agios, Rafael Pharmaceuticals have relevant expertise
### Safety Concerns
- **Glucose homeostasis:** Risk of hypoglycemia
- **Neuronal toxicity:** Neurons also use glycolysis, especially during stress
- **Systemic effects:** Difficult to achieve brain selectivity
- **Seizure risk:** 2-DG can cause seizures at high doses
### Cost & Timeline
- **Discovery-IND:** $10-18M, 3-4 years (CNS-selective delivery systems)
- **Major technical hurdle:** Achieving microglial selectivity
- **Phase I:** $15-25M, 2 years (extensive safety monitoring)
- **Total to proof-of-concept:** $35-60M, 6-8 years
**Verdict:** **Low-moderate feasibility** - established targets but selectivity challenges
---
## Hypothesis 3: TREM2 Conformational Stabilizers
**Revised Confidence: 0.35**
### Druggability Assessment
**Target Class:** Immunoglobulin superfamily receptor - challenging
**Chemical Matter:**
- **Conformational stabilizers:** Very limited precedent
- **Allosteric modulators:** Few successful examples for Ig-family receptors
- **Likely approach:** Antibody-based or protein therapeutics
### Existing Tools/Clinical Candidates
**TREM2 agonists:**
- **AL002** (Alector) - TREM2 agonist antibody, Phase I for AD
- **Academic tools:** Various research antibodies, limited characterization
**TREM2 modulators:** Very limited pipeline
### Competitive Landscape
- **TREM2 space:** Alector is the clear leader
- **Microglial targets:** Crowded with many approaches
- **Technical risk:** Extremely high given limited mechanistic understanding
### Safety Concerns
- **Unknown effects:** No precedent for conformational stabilization approach
- **TREM2 loss-of-function is pathogenic:** Risk of inadvertent inhibition
- **Immunogenicity:** Likely if protein-based approach
### Cost & Timeline
- **Discovery-IND:** $20-35M, 5-7 years (high technical risk)
- **Failure probability:** 85%+ given limited precedent
- **Total investment at risk:** $50-100M+
**Verdict:** **Low feasibility** - technically very challenging, limited validation
---
## Hypothesis 7: Optogenetic Microglial Deactivation
**Revised Confidence: 0.25**
### Druggability Assessment
**Target Class:** Optogenetics - not a drug target per se
**Approach:** Gene therapy + implantable device
- **Viral vectors:** AAV, lentivirus for opsin delivery
- **Light delivery:** Implanted LED arrays or fiber optics
- **Regulatory path:** Combination product (gene therapy + device)
### Existing Tools/Clinical Candidates
**Optogenetic clinical trials:**
- **RST-001** (Allergan/RetroSense) - retinal optogenetics, Phase I/II
- **PIONEER** (GenSight) - retinal optogenetics, Phase III
- **No CNS optogenetic trials** for neurodegenerative diseases
### Competitive Landscape
- **Gene therapy space:** Crowded, high regulatory burden
- **Neurotechnology:** Companies like Neuralink, Synchron in adjacent spaces
- **Academic interest:** Strong but minimal commercial development
### Safety Concerns
- **Surgical risk:** Brain implantation procedures
- **Long-term device complications:** Infection, hardware failure
- **Immune response:** To viral vectors and opsin proteins
- **Unknown long-term effects:** Of chronic microglial suppression
### Cost & Timeline
- **Preclinical development:** $25-40M, 4-6 years
- **Regulatory approval:** Extremely complex (FDA combination product pathway)
- **Clinical trials:** $75-150M, 8-12 years
- **Total to market:** $150-300M+, 12-18 years
**Verdict:** **Very low feasibility** - massive regulatory and commercial barriers
---
## Overall Recommendations
### Most Promising (Worth Investment):
1. **P2Y12 Inverse Agonists** - Clear medicinal chemistry path, druggable target
2. **C1q Mimetic Decoys** - Strong biology despite technical challenges
### Moderate Potential (Requires More Validation):
3. **CX3CR1 PAMs** - Good target class but novel mechanism needs validation
4. **Glycolysis Inhibitors** - Established chemistry but selectivity challenges
### High Risk/Low Priority:
5. **TREM2 Conformational Stabilizers** - Technically very challenging
6. **Optogenetic Approaches** - Clinical translation barriers too high
### Key Success Factors:
- **CNS penetration:** Critical for all approaches
- **Selectivity:** Must avoid systemic immune suppression
- **Biomarkers:** Need to measure target engagement and synaptic preservation
- **Patient stratification:** May need to focus on early-stage AD patients
**Total sector investment needed:** $200-400M over 10-15 years across multiple approaches to have reasonable probability of clinical success.